Risk reduction and health promotion behaviors following genetic testing for adult-onset disorders

被引:40
作者
Beery, Theresa A.
Williams, Janet K.
机构
[1] Univ Cincinnati, Coll Nursing, Inst Nursing Res, Cincinnati, OH 45221 USA
[2] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA
来源
GENETIC TESTING | 2007年 / 11卷 / 02期
关键词
D O I
10.1089/gte.2006.0527
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Although clinical genetic testing is available for over 1,000 inherited disorders, consequences of predictive genetic testing have been most extensively examined for hereditary breast and ovarian cancer (HBOC), hereditary colon cancer, and Huntington disease (HD). These focus primarily on psychological, ethical, legal, and social aspects of genetic testing. Genetic testing may also provide information that can lead to behaviors that promote health and reduce risk for disease, reflecting options available for the disorder for which the person is at risk. However, regardless of condition, people completing a genetic test may inform relatives about the results of the test and implications for their risk to develop the condition. Literature on risk reduction behaviors and communication focuses on families with HBOC or colorectal cancer. Few reports document behaviors for other conditions. This paper presents a systematic review of the research literature on risk reduction and health promotion behaviors following clinical genetic testing for adult onset conditions, primarily HBOC, familial colon cancers, and HD. Insights gleaned from this review are discussed as a basis for planning monitoring of health promotion and risk-reduction behaviors for genetic testing for present and future use.
引用
收藏
页码:111 / 123
页数:13
相关论文
共 101 条
[11]   Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer [J].
Claes, E ;
Evers-Kiebooms, G ;
Decruyenaere, M ;
Denayer, L ;
Boogaerts, A ;
Philippe, K ;
Legius, E .
BEHAVIORAL MEDICINE, 2005, 31 (03) :93-105
[12]   Predictive testing for hereditary nonpolyposis colorectal cancer: Subjective perception regarding colorectal and endometrial cancer, distress, and health-related behavior at one year post-test [J].
Claes, E ;
Denayer, L ;
Evers-Kiebooms, G ;
Boogaerts, A ;
Philippe, K ;
Tejpar, S ;
Devriendt, K ;
Legius, E .
GENETIC TESTING, 2005, 9 (01) :54-65
[13]   PSYCHOLOGICAL COSTS AND BENEFITS OF PREDICTIVE TESTING FOR HUNTINGTONS-DISEASE [J].
CODORI, AM ;
BRANDT, J .
AMERICAN JOURNAL OF MEDICAL GENETICS, 1994, 54 (03) :174-184
[14]   Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma [J].
Collins, V ;
Meiser, B ;
Gaff, C ;
John, DJB ;
Halliday, J .
CANCER, 2005, 104 (02) :273-281
[15]   Communication of BRCA1 and BRCA2 results to at-risk Relatives:: A cancer risk assessment program's experience [J].
Costalas, JW ;
Itzen, M ;
Malick, J ;
Babb, JS ;
Bove, B ;
Godwin, AK ;
Daly, MB .
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2003, 119C (01) :11-18
[16]   Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000 [J].
Creighton, S ;
Almqvist, EW ;
MacGregor, D ;
Fernandez, B ;
Hogg, H ;
Beis, J ;
Welch, JP ;
Riddell, C ;
Lokkesmoe, R ;
Khalifa, M ;
MacKenzie, J ;
Sajoo, A ;
Farrell, S ;
Robert, F ;
Shugar, A ;
Summers, A ;
Meschino, W ;
Allingham-Hawkins, D ;
Chiu, T ;
Hunter, A ;
Allanson, J ;
Hare, H ;
Schween, J ;
Collins, L ;
Sanders, S ;
Greenberg, C ;
Cardwell, S ;
Lemire, E ;
MacLeod, P ;
Hayden, MR .
CLINICAL GENETICS, 2003, 63 (06) :462-475
[17]   Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer [J].
de Leon, MP ;
Benatti, P ;
Di Gregorio, C ;
Pedroni, M ;
Losi, L ;
Genuardi, M ;
Viel, A ;
Fornasarig, M ;
Lucci-Cordisco, E ;
Anti, M ;
Ponti, G ;
Borghi, F ;
Lamberti, I ;
Roncucci, L .
BRITISH JOURNAL OF CANCER, 2004, 90 (04) :882-887
[18]  
Di Prospero LS, 2001, CAN MED ASSOC J, V164, P1005
[19]   Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations [J].
DiGianni, LM ;
Rue, M ;
Emmons, K ;
Garber, JE .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (01) :70-75
[20]  
DiGianni LM, 2003, CANCER EPIDEM BIOMAR, V12, P321